SCHEMBL6769965

SCHEMBL6769965

CON=C(CC1=CCCN(C)C1)CN1CCCC1=O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
CHRM2 P08172 2/20 0.34
CHRM5 P08912 2/20 0.34
CHRM1 P11229 2/20 0.34
LMNA P02545 1/20 0.34
CHRM4 P08173 1/20 0.34
THRB P10828 1/20 0.34
CHRM3 P20309 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.33
BLM P54132 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6769960 1.00 TSHR (0.36) TSHRSMN1; SMN2CHRM2CHRM5CHRM1
SCHEMBL6771063 0.87 TSHR (0.38) TSHRSMN1; SMN2CHRM2CHRM5CHRM1
SCHEMBL6771065 0.87 TSHR (0.38) TSHRSMN1; SMN2CHRM2CHRM5CHRM1
SCHEMBL6767025 0.84 LMNA (0.39) TSHRSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL6767022 0.84 LMNA (0.39) TSHRSMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL6770486 0.79 CHRM2 (0.44) SMN1; SMN2CHRM2CHRM5CHRM1LMNA
SCHEMBL6770482 0.79 CHRM2 (0.44) SMN1; SMN2CHRM2CHRM5CHRM1LMNA
SCHEMBL6777311 0.74 CHRM2 (0.43) CHRM2CHRM5CHRM1LMNACHRM4
SCHEMBL6777308 0.74 CHRM2 (0.43) CHRM2CHRM5CHRM1LMNACHRM4
SCHEMBL6770818 0.70 CHRNB2 (0.43) TSHRCHRM2CHRM5CHRM1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716857-B2 1-(3-HYDROCARBYLOXYIMINO-3-(1-ALKYL-1,2,5,6-TETRAHYDROPYRID-3-YL) -ALKYLPYRROLIDIN-2-ONE DERIVATIVES; RECEPTIVITY; ANALGESICS, GLAUCOMA, PSYCHOSIS, SCHIZOPHRENIA, ANXIOLYTIC AGENTS, BIPOLAR DISORDERS; ANTIDEPRESSANTS; SLEEP DISORDERS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2004-04-06 US claimed
US-20030119880-A1 Tetrahydropyridine derivatives acting on muscarinic acetylcholine receptors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2003-06-26 US claimed
US-6716857-B2 1-(3-HYDROCARBYLOXYIMINO-3-(1-ALKYL-1,2,5,6-TETRAHYDROPYRID-3-YL) -ALKYLPYRROLIDIN-2-ONE DERIVATIVES; RECEPTIVITY; ANALGESICS, GLAUCOMA, PSYCHOSIS, SCHIZOPHRENIA, ANXIOLYTIC AGENTS, BIPOLAR DISORDERS; ANTIDEPRESSANTS; SLEEP DISORDERS KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2004-04-06 US disclosed
US-20030119880-A1 Tetrahydropyridine derivatives acting on muscarinic acetylcholine receptors KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119880-A1 Tetrahydropyridine derivatives acting on muscarinic acetylcholine receptors CHRM1, CHRM3, CHRM2 TSHR 92/4885SMN1; SMN2 1483/4885CHRM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.